title: [IgG4-related disease treatment in 2014: Update and literature review].
abstract: IgG4-related disease is an inflammatory disorder characterized by a polyclonal lymphoplasmacytic tissue infiltrate, with numerous IgG4+ plasmocytes, evolving toward fibrosis. The disease is heterogeneous and affects several tissues and organs synchroneously or metachroneously. Both the fibrosis and the tumor forming characteristics of the disease can be responsible of irreversible tissue damage. For these reasons treatment is usually necessary. A dramatic response is usually observed with steroid treatment but relapses are frequent. Immunosuppressive agents and rituximab are used as second line treatments. We review here previous studies on treatment and suggest general recommendations for the treatment and follow up of patients with IgG4-related disease.
authors.affiliation: Service de médecine interne, hôpital de la Timone, AP-HM, Aix-Marseille université, 264, rue Saint-Pierre, 13385 Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Grados
authors.affiliation: Service de médecine interne, hôpital de la Timone, AP-HM, Aix-Marseille université, 264, rue Saint-Pierre, 13385 Marseille, France. Electronic address: mikael.ebbo@ap-hm.fr.
authors.forename: M
authors.initials: M
authors.lastname: Ebbo
authors.affiliation: Service de médecine interne, hôpital Nord, AP-HM, Aix-Marseille université, 13915 Marseille, France.
authors.forename: E
authors.initials: E
authors.lastname: Jean
authors.affiliation: Service de médecine interne, hôpital de la Timone, AP-HM, Aix-Marseille université, 264, rue Saint-Pierre, 13385 Marseille, France.
authors.forename: E
authors.initials: E
authors.lastname: Bernit
authors.affiliation: Service de médecine interne, hôpital de la Timone, AP-HM, Aix-Marseille université, 264, rue Saint-Pierre, 13385 Marseille, France.
authors.forename: J-R
authors.initials: JR
authors.lastname: Harlé
authors.affiliation: Service de médecine interne, hôpital de la Timone, AP-HM, Aix-Marseille université, 264, rue Saint-Pierre, 13385 Marseille, France.
authors.forename: N
authors.initials: N
authors.lastname: Schleinitz
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000473:pathology; D005355:Fibrosis; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D005938:Glucocorticoids; D007074:Immunoglobulin G; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab
keywords: Autoimmune pancreatitis; Corticosteroids; Corticoïdes; IgG4-related disease; Maladie associée aux IgG4; Pancréatite auto-immune; Rituximab; Traitement; Treatment